WO2000007598A1 - Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption - Google Patents
Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption Download PDFInfo
- Publication number
- WO2000007598A1 WO2000007598A1 PCT/GB1999/002509 GB9902509W WO0007598A1 WO 2000007598 A1 WO2000007598 A1 WO 2000007598A1 GB 9902509 W GB9902509 W GB 9902509W WO 0007598 A1 WO0007598 A1 WO 0007598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- alkyl
- group
- substituted
- trifluoromethyl
- Prior art date
Links
- 0 C(C1)*CC1C1*CCCC1 Chemical compound C(C1)*CC1C1*CCCC1 0.000 description 9
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the treatment or prevention of abnormal bone resorption by the administration of a NK-1 receptor antagonist, optionally in combination with one or more active agents from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
- abnormal bone resorption means a degree of bone resorption that exceeds the degree of bone formation, either locally, or in the skeleton as a whole. "Abnormal bone resorption” can also be associated with the formation of bone having an abnormal structure.
- disorders in humans and other mammals involve or are associated with abnormal bone resorption.
- Such disorders include, but are not limited to, osteoporosis, Paget's disease, peridontal disease, periprosthetic bone loss or osteolysis, and hypercalcemia of malignancy.
- the most common of these disorders is osteoporosis, which in its most frequent manifestation occurs in postmenopausal women.
- Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
- Osteoporotic patients usually experience bone resorption in excess of bone formation, causing chronic bone loss. Because osteoporosis, as well as other disorders associated with ongoing bone loss, are chronic conditions, it is believed that appropriate therapy will generally require chronic treatment.
- Multinucleated cells called osteoclasts are responsible for a process known as bone resorption.
- the bone resorption rate exceeds the bone formation rate, causing net bone loss.
- bisphosphonates are selective inhibitors of osteoclastic bone resorption, making these compounds important therapeutic agents in the treatment or prevention of a variety of generalized or localized bone disorders caused by or associated with abnormal bone resorption. See H. Fleisch, Bisphosphonates In Bone Disease, From The Laboratory To The Patient, 2nd Edition, Parthenon Publishing (1995), which is incorporated by reference herein in its entirety. At present, a great amount of preclinical and clinical data exists for the potent bisphosphonate compound alendronate.
- Peak bone mass in women is achieved at around 30-35 years of age. Bone mass is then relatively stable until the perimenopausal period (usually the late fifth decade of life). The rate of bone loss accelerates markedly during the early post menopausal period to a rate of 3-4% annually, especially at sites with a high component of trabecular bone. After 8-10 years of menopausal life, the bone loss rate slowly stabilizes at about 1% annually.
- the average woman has a greater than 40% chance of developing at least one osteoporotic fracture during her lifetime. Osteoporotic fractures, especially of the hip, occur in 16% of all women reaching 80 years of age, and are associated with a marked reduction in the quality of life and high cost of treatment. The total costs and morbidity associated with all osteoporotic fractures are certain to substantially exceed those of hip fracture alone, although precise estimates are not available.
- estrogen replacement therapy Apart from bisphosphonates such as alendronate, other generally recognised therapies for prevention of osteoporosis are estrogen replacement therapy, raloxifene, a selective estrogen receptor modulator, and calcitonin.
- administration of estrogen can help reduce post menopausal symptoms such as vasomotor instability, vaginal atrophy, and increased incidence of cardiovascular problems, possibly associated with a deterioriation in the lipid profile.
- estrogen treatment is also associated with some serious risks, including endometrial carcinoma, symptomatic gall bladder disease, deep vein thrombosis and an increased incidence of breast cancer. Although some of these risks can be lowered by addition of progestins to the therapeutic regimen, a large proportion of women will not accept long-term estrogen treatment mainly because of breakthrough bleeding and safety concerns.
- Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P.
- substance P substance P
- NK-1 receptor antagonists to treat or prevent abnormal bone resorption, has not been elucidated.
- NK-1 receptor antagonists are effective in the treatment of abnormal bone resorption, as evidenced by their effect on bone density in vivo in an animal model of inflammatory joint disease. Furthermore, a combination of a NK-1 receptor antagonist with a bisphosphonate may provide enhanced inhibition of bone resorption over that provided by the bisphosphonate alone. They may also allow for a reduced dosage or frequency of dosing with the bisphosphonate which would be particularly advantageous when side-effects are a liability with high dosage or chronic adminstration regimens.
- the present invention accordingly provides the use of a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
- the present invention also provides a method for the treatment or prevention of abnormal bone resorption, which method comprises administration to a patient in need of such treatment an effective amount of a NK-1 receptor antagonist.
- a pharmaceutical composition for the treatment or prevention of abnormal bone resorption comprising a NK-1 receptor antagonist, together with at least one pharmaceutically acceptable carrier or excipient.
- the NK-1 receptor antagonist may be administered in combination with one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
- the present invention therefore further provides the use of a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
- the present invention also provides a method for the treatment or prevention of abnormal bone resorption, which method comprises administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators and peptide hormones, such that together they give effective relief.
- a pharmaceutical composition comprising a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at least one pharmaceutically acceptable carrier or excipient.
- NK-1 receptor antagonist and the additional active agent(s) may be present as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of abnormal bone resorption.
- Such combined preparations may be, for example, in the form of a twin pack.
- a product comprising a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of abnormal bone resorption.
- the methods and compositions of the present invention are useful for both treating and preventing abnormal bone resorption and conditions associated therewith.
- the NK-1 receptor antagonist when used in combination therapy, is administered in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen receptor modulators, and peptide hormones.
- the NK-1 receptor antagonist When used in combination therapy, is preferably administered in combination with a bisphosphonate.
- Conditions associated with abnormal bone resorption include both generalized and localized bone loss.
- generalized bone loss means bone loss at multiple skeletal sites or throughout the skeletal system.
- localized bone loss means bone loss at one or more specific, defined skeletal sites.
- Osteoporosis is most common in post-menopausal women, wherein estrogen production has diminished. However, osteoporosis can also be glucocorticoid-induced and has been observed in males due to age and reduced androgen production. Osteoporosis can be induced by disease, e.g. rheumatoid arthritis; by secondary causes, e.g., glucocorticoid therapy; or by no identifiable cause, i.e. idiopathic osteoporosis, possibly of inherited origin. In the present invention, preferred methods include the treatment or prevention of abnormal bone resorption in osteoporotic humans. Localized bone loss has been associated with periodontal disease and periprosthetic osteolysis where bone resorption has occurred in proximity to a dental or orthopaedic prosthetic implant.
- Generalized or localized bone loss can occur from disuse, often a problem for those confined to a bed or a wheelchair, those who have an immobilized limb set in a cast or held in traction, or those who suffer permanently disabling strokes.
- osteoporosis including post-menopausal osteoporosis, glucocorticoid- induced osteoporosis, male osteoporosis, disease-induced osteoporosis, and idiopathic osteoporosis; Paget's disease; abnormally increased bone turnover; hypercalcemia of malignancy; osteogensis imperfecta; periodontal disease; periprosthetic osteolysis; and abnormal bone resorption associated with immunosuppressive therapy.
- osteoporosis including post-menopausal osteoporosis, glucocorticoid- induced osteoporosis, male osteoporosis, disease-induced osteoporosis, and idiopathic osteoporosis
- Paget's disease abnormally increased bone turnover; hypercalcemia of malignancy; osteogensis imperfecta; periodontal disease; periprosthetic osteolysis; and abnormal bone resorption associated with immunosuppressive therapy.
- pharmaceutically effective amount means that amount of the NK-1 receptor antagonist and (where present) the additional active agent(s), that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen.
- a preferred pharmaceutically effective amount of the NK-1 receptor antagonist and (where present) the additional active agent(s) is a bone resorption inhibiting amount.
- bone resorption inhibiting means preventing bone resorption by the direct or indirect alteration of osteoclast formation or activity. Inhibition of bone resorption refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
- the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered, according to the dosing schedule chosen, until the desired therapeutic effect is achieved, i.e. up to the time that the clinical or medical effect sought for the disease or condition being treated is observed by the clinician or researcher.
- the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered until the desired change in bone resorption rate, bone mass, or bone structure is observed. In such instances, achieving an increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives.
- the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered for as long as necessary to prevent the undesired condition.
- Non-limiting examples of administration periods can range from about 2 weeks to the remaining lifespan of the mammal.
- administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.
- mammal as used herein include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and humans, the latter being preferred.
- compositions of the present invention are especially useful for the treatment or prevention of abnormal bone resorption where the use of a bisphosphonate or estrogen replacement therapy is generally prescribed.
- a NK-1 receptor antagonist optionally in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones in accordance with the present invention, it is now also possible to treat or prevent abnormal bone resorption in patients for whom conventional therapy might not be wholly successful or where patient compliance with existing therapeutic regimens is problematic.
- NK-1 receptor antagonists of use in the present invention are described in published European Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in International Patent Specification Nos
- NK-1 receptor antagonists are those described in European Patent Specification No. 0 577 394, especially compounds of formula (I):
- R 1 is selected from the group consisting of:
- Ci- ⁇ alkyl substituted with one or more of the substituents selected from:
- heterocycle wherein the heterocycle is selected from the group consisting of:
- R 9 and R 10 are as defined above, R 2 and R 3 are independently selected from the group consisting of: (1) hydrogen;
- Ci- ⁇ alkyl (3) C 2 -6alkenyl, and (5) phenyl;
- X is -O-
- R 5 is phenyl, unsubstituted or substituted with halo
- R 6 , R 7 and R 8 are independently selected from the group consisting of:
- Y is -0-
- Z is hydrogen or C ⁇ - alkyl; and pharmaceutically acceptable salts thereof.
- Particularly preferred compounds of formula (I) are:
- NK-1 receptor antagonists are those described in
- a 1 is fluorine or CF 3 ;
- a 2 is fluorine or CF 3 ;
- a 3 is fluorine or hydrogen;
- Z is Ci- ⁇ alkylene or C3-6cycloalkylene
- R 7 is hydrogen, C 1-4 alkyl, C3-7cycloalkyl or C3- 7 cycloalkylC ⁇ - alkyl, or
- R 8 is hydrogen, C ⁇ - alkyl, C3-7cycloalkyl or C 3 -7cycloalkylC ⁇ - alkyl, or C 2 - alkyl substituted by one or two substituents selected from C ⁇ - alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R 7 , R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O) 2 or a second nitrogen atom which will be part of a NH or NR C moiety where R c is C ⁇ - alkyl optionally substituted by hydroxy or C ⁇ - alkoxy; or R 7 , R 8 and the nitrogen atom to which they are attached form
- X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo
- Y is a C ⁇ - alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is C ⁇ - alkyl, R 6 is susbstituted at least by a group of formula ZNR 7 R 8 as defined above.
- Particularly preferred compounds of formula (II) include: 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-l,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(l-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(l,2,4-triazol-3-yl)methylmorpholine; and pharmaceutically acceptable salts thereof.
- NK-1 receptor antagonists are those described in European Patent Specification No. WO 95/23798, especially compounds of formula (III):
- R 2 and R 3 are independently selected from the group consisting of:
- R 6 , R 7 and R 8 are independently selected from the group consisting of:
- R n , R 12 and R 13 are independently selected from the group consisting of:
- A is unsubstituted l- ⁇ alkyl
- B is selected from the group consisting of:
- p is 0 or 1;
- X is selected from:
- Y is -0-
- Z is hydrogen or Ci- ⁇ alkyl; and pharmaceutically acceptable salts thereof.
- Particularly preferred compounds of formula (III) include: (1) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo- lH,4H-l,2,4-triazolo)methyl)morpholine N-oxide; (2) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(4- (ethoxycarbonyloxy-l-ethyl)-5-oxo-lH-l,2,4- triazolo)methyl)morpholine;
- NK-1 receptor antagonists are those described in
- R 1 represents hydrogen, hydroxy, Ci- ⁇ alkyl, C2-6alkenyl, C3-7cycloalkyl, C3-7cycloalkylC ⁇ - alkyl, Ci- ⁇ alkoxy, fluoroCi- ⁇ alkoxy, C ⁇ -6alkoxy C ⁇ - alkyl, Ci- ⁇ alkoxyC i- alkoxy , fluoroC ⁇ -6alkoxyC ⁇ -4 alkyl, C 2 -6alkenyloxy, C3-7cycloalkoxy, C3-7cycloalkylCi- alkoxy, phenoxy, benzyloxy, cyano, halogen, NR a R , SR a , SOR a , S0 2 R a , OS0 2 R a , NR a COR 14 , COR a , C0 2 R a or CONR a R b where R a and R b each independently represent hydrogen, C ⁇ - alkyl or fluoro
- R 3 represents hydrogen, halogen, Ci- ⁇ alkyl, fluoroCi- ⁇ alkyl, C ⁇ -6alkoxy, fluoroCi- ⁇ alkoxy, C3-7cycloalkyl, C3-7cycloalkylC ⁇ - 4 alkyl, cyano, SR a , SOR a , S0 2 R a , NR a R b , NR a COR* 4 , COR a , C0 2 R a , CONR a R or C ⁇ -4 alkyl substituted by cyano, C ⁇ 2R a or CONR a R b where R a and R b are as previously defined;
- R 4 represents hydrogen, halogen, Ci- ⁇ alkyl, Ci- ⁇ alkoxy, CF3, OCF3, N0 2 , CN, SR a , SOR a , S0 2 R a , C0 2 R a , CONR a R b , C 2 -6alkenyl, C 2 - 6 alkynyl or C ⁇ - alkyl substituted by C ⁇ - alkoxy, where R a and R b are as previously defined; and the broken line represents an optional double bond; and pharmaceutically acceptable salts thereof.
- Particularly preferred compounds of formula (IV) include: (3E,5 J R,6S)-3-(2-methoxy-5-(trifluoromethoxy)phenyl)-6-phenyl-l-oxa-7- aza-spiro[4.5]decane;
- NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
- Y is (CH 2 )n wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said (CH 2 )n may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH 2 )n may optionally be substituted with R 4 , and wherein any one of the carbon atoms of said (CH2) n may optionally be substituted with R 7 ;
- Z is (CH2)m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH2) m may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH2)m may optionally be substituted with R 8 ;
- R 1 is hydrogen or Ci-salkyl optionally substituted with hydroxy, C ⁇ - alkoxy or fluoro;
- R 2 is a radical selected from hydrogen, C ⁇ -6 straight or branched alkyl, C3-7cycloalkyl wherein one of the CH2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl-C2-6alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl - C2-6alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, C1-6 alkyl, d- ⁇ alk
- R 5 is hydrogen, phenyl or Ci- ⁇ alkyl; or R 2 and R 5 together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the CH 2 groups in said ring may optionally be replaced by oxygen, NH or sulfur;
- R 3 is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of the (CH 2 ) groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3-7cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, Ci- ⁇ alkyl, Ci- ⁇ alkoxy, trifluoromethyl, amino, Ci- ⁇ alkylamino, -CO-NH- Ci- ⁇ alkyl, Ci-
- R 4 and R 7 are each independently selected from hydroxy, halogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, Ci- ⁇ alkylamino, di-C ⁇ -6alkylamino, Ci- ⁇ alkoxy, Ci- ⁇ alkyl-O-CO, Ci- ⁇ alkyl-O-CO-Ci-ealkyl, Ci- ⁇ alkyl-CO-O, Ci- ⁇ alkyl-CO-Ci-ealkyl-O-, Ci- ⁇ alkyl-CO-, C ⁇ -6alkyl-CO-C ⁇ -6alkyl, and the radicals set forth in the definition of R 2 ;
- R 6 is -NHCOR 9 , -NHCH 2 R 9 , S0 2 R 8 or one of the radicals set forth in any of the definitions of R 2 , R 4 and R 7 ;
- R 9 is Ci- ⁇ alkyl, hydrogen, phenyl or phenylCi- ⁇ alkyl; with the proviso that (a) when m is 0, R 8 is absent, (b) when R 4 , R 6 , R 7 or R 8 is as defined in R 2 , it cannot form together with the carbon to which it is attached ,a ring with R 5 , and (c) when R 4 and R 7 are attached to the same carbon atom, then either each of R 4 and R 7 is independently selected from hydrogen, fluoro and Ci- ⁇ alkyl, or R 4 and R 7 , together with the carbon to which they are attached, for a C3-6 saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached.
- a particularly preferred compound of formula (V) is (2S,3S)-cis-3-(2- methoxybenzylamino)-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
- Another class of NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No. WO 93/21155, i.e. compounds of formula (VI):
- radicals R are phenyl radicals optionally 2- or 3-substituted by a halogen atom or a methyl radical;
- R 1 is optionally substituted phenyl, cyclohexadienyl, naphthyl, indenyl or optionally substituted heterocycle;
- R 2 is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyl oxycarbonyl, benzyloxy carbonyl, amino or acylamino;
- R 3 is optionally 2-substituted phenyl; R 4 is OH or fluorine when R 5 is H; or R 4 and R 5 are OH ; or R 4 and R 5 together form a bond.
- a particularly preferred compound of formula (VI) is (3aS, 4S, 7aS)- 7,7-diphenyl-4-(2-methoxyphenyl)-2-[(2S)-(2-methoxyphenyl)propionyl] perhydroisoindol-4-ol; or a pharmaceutically acceptable salt thereof.
- NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No. 0 591 040, i.e. compounds of formula (VII):
- Ar represents an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group
- T represents a bond, a hydroxymethylene group, a C ⁇ - alkoxymethylene group or a Ci-salkylene group
- Ar' represents a phenyl group which is unsubstituted or substituted by one or more substituents selected from halogen, preferably chlorine or fluorine, trifluoromethyl, C ⁇ - alkoxy, C ⁇ - alkyl where the said substituents may be the same or different; a thienyl group; a benzothienyl group; a naphthyl group; or an indolyl group;
- R represents hydrogen, C ⁇ - alkyl, ⁇ -C ⁇ - alkoxyC ⁇ - alkyl, or ⁇ -C 2 - alkanoyloxyC2- alkyl;
- Q represents hydrogen; or Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4- butylene group;
- Am + represents the radical
- Xi, X 2 and X3 together with the nitrogen atom to which they are attached, form an azabicyclic or azatricyclic ring system optionally substituted by a phenyl or benzyl group; and A- represents a pharmaceutically acceptable anion.
- a particularly preferred compound of formula (VII) is (+) l-[2-[3-
- NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
- R 1 represents an optionally substituted aralkyl, aryloxyalykl, heteroaralkyl, aroyl, heteroaroyl, cycloalkylcarbonyl, aralkanoyl, heteroarylalkanoyl, aralkoxycarbonyl or arylcarbamoyl group or the acyl group of an ⁇ -amino acid optionally N-substituted by a lower alkanoyl or carbamoyl-lower alkanoyl group;
- R 2 represents cycloalkyl or an optionally substituted aryl or heteroaryl group
- R 3 represents hydrogen, alkyl, carbamoyl or an alkanoyl or alkenoyl group optionally substituted by carboxy or esterified or amidated carboxy
- R 4 represents an optionally substituted aryl group or an optionally partially saturated heteroaryl group
- Xi represents methylene, ethylene, a bond, an optionally ketalised carbonyl group or an optionally etherified hydroxymethylene group
- X 2 represents alkylene, carbonyl or a bond
- X 3 represents carbonyl, oxo-lower alkyl, oxo(aza)-lower alkyl, or an alkyl group optionally substituted by phenyl, hydroxymethyl, optionally esterified or amidated carboxy, or (in other than the ⁇ -position) hydroxy.
- a particularly preferred compound of formula (VIII) is (2R", 4S * )-2- benzyl-l-(3,5-dimethylbenzoyl)-N-(4-quinolinylmethyl)-4-piperidineamine; or a pharmaceutically acceptable salt thereof.
- NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No. 0 443 132, i.e. compounds of formula (IX)
- R 1 is aryl, or a group of the formula:
- X is CH or N
- Z is O or N-R 5 , in which R 5 is hydrogen or lower alkyl; R 2 is hydroxy or lower alkoxy;
- R 3 is hydrogen or optionally substituted lower alkyl
- R 4 is optionally substituted ar(lower)alkyl
- A is carbonyl or sulfonyl
- Y is a bond or lower alkenylene.
- a particularly preferred compound of formula (IX) is the compound of formula (IXa)
- NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No. WO 92/17449, i.e. compounds of the formula (X)
- R 1 is aryl selected from indanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms, wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3-7cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from chloro, fluoro, bromo, iodo, nitro, C ⁇ - ⁇ oalkyl optionally substituted with from one to three fluoro groups, Ci-ioalkoxy optionally substituted with from one to three fluoro groups, amino, C ⁇ - ⁇ oalkyl-S-, C ⁇ - ⁇ oalkyl-S(O)-, C ⁇ - ⁇ oalkyl-S ⁇ 2-, pheny
- C ⁇ - ⁇ oalkyl-S0 2 NH-C ⁇ - ⁇ oakyl-, Ci-ioalkylamino-diCi-ioalkyl-, cyano, hydroxy, cycloalkoxy having 3 to 7 carbon atoms, Ci- ⁇ alkylamino, Ci- ⁇ dialkylamino, HC(0)NH- and Cn 0 alkyl-C(O)NH-; and R 2 is thienyl, benzhydryl, naphthyl or phenyl optionally substituted with from one to three substituents independently selected from chloro, bromo, fluoro, iodo, cycloalkoxy having 3 to 7 carbon atoms, Ci-ioalkyl optionally substituted with from one to three fluoro groups and Ci-ioalkoxy optionally substituted with from one to three fluoro groups.
- a particularly preferred compound of formula (X) is (2S,3S)-3-(2- methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
- Another class of NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No. WO 95/08549, i.e. compounds of formula (XI)
- R 1 is a C ⁇ - alkoxy group
- R 2 is
- R 3 is a hydrogen or halogen atom
- R 4 and R 5 may each independently represent a hydrogen or halogen atom, or a C ⁇ - alkyl, C ⁇ - alkoxy or trifluoromethyl group
- R 6 is a hydrogen atom, a C ⁇ - alkyl, (CH 2 ) m cyclopropyl, - S(0)nC ⁇ - alkyl, phenyl, NR 7 R 8 , CH 2 C(0)CF 3 or trifluoromethyl group;
- R 7 and R 8 may each independently represent a hydrogen atom, or a C ⁇ - alkyl or acyl group; x represents zero or 1; n represents zero, 1 or 2; and m represents zero or 1.
- Particularly preferred compounds of formula (XI) are (2-methoxy-5- tetrazol-l-yl-benzyl)-([2S,3S]-2-phenyl-piperidin-3-yl)-amine; and [2- methoxy-5-(5-trifluoromethyl-tetrazol-l-yl)-benzyl]-([2S,35]-2-phenyl- piperidin-3-yl)-amine; or a pharmaceutically acceptable salt thereof.
- Another class of tachykinin antagonists of use in the present invention is that described in International Patent Specification No. WO 95/14017, i.e. compounds of formula (XII)
- R is phenyl, 2- or 3-indolyl, 2- or 3-indolinyl, benzothienyl, benzofuranyl, or naphthyl; which R groups may be substituted with one or two halo, C ⁇ -3alkoxy, trifluoromethyl, C ⁇ - 4 alkyl, phenyl-Ci-3alkoxy, or C ⁇ - 4 alkanoyl groups; R 1 is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahydropyridinyl, quin
- R 1 groups may be substituted with phenyl, piperazinyl, C 3 - 8 cycloalkyl, benzyl, piperidinyl, pyridinyl, pyrimidinyl, C -6alkanoylamino, pyrrolidinyl, C 2 _6alkanoyl, or C ⁇ - alkoxy carbonyl ; any one of which groups may be substituted with halo, C ⁇ - 4 alkyl, C ⁇ - alkoxy, trifluoromethyl, amino, C ⁇ - 4 alkylamino, di(C ⁇ -4 alkyl)amino, or C 2 -4alkanoylamino; or R 1 is amino, a leaving group, hydrogen, C ⁇ -4 alkylamino, or di(C ⁇ - 4 alkyl)amino;
- R 5 is pyridyl, anilino-(Ci-3alkyl)-, or anilinocarbonyl;
- R 2 is hydrogen, C ⁇ -4 alkyl, C ⁇ - alkylsulfonyl, carboxy-(C ⁇ _3alkyl)-, C ⁇ - 3 alkoxycarbonyl-(C 1 -3alkyl)-, or -CO-R 6 ;
- R 6 is hydrogen, C ⁇ - 4 alkyl, C ⁇ -3haloalkyl, phenyl, C ⁇ -3hydroxyalkyl, amino, C ⁇ -4 alkylamino, di(C ⁇ - 4 alkyl)amino, or -(CH 2 ) q -R 7 ; q is zero to 3;
- R 7 is carboxy, Ci- 4 alkoxycarbonyl, C ⁇ -4 alkylcarbonyloxy, amino, C ⁇ - 4 alkylamino, di(Ci- 4 alkyl)amino, Ci-ealkoxycarbonylamino, or phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolinyl, phenyl-(C ⁇ - alkyl)-, quinolinyl-(C ⁇ - 4 alkyl)-, isoquinolinyl-(C ⁇ - 4 alkyl)-, reduced quinolinyl- (C ⁇ -4 alkyl)-, reduced isoquinolinyl-(C ⁇ - 4 alkyl)-, benzoyl-C ⁇ -3alkyl; any one of which aryl or heterocyclic R 7 groups may be substituted
- R 8 is hydrogen or Ci- ⁇ alkyl
- R 3 is phenyl, phenyl-(Ci-6alkyl)-, C3-8cycloalkyl, Cs-scycloalkenyl,
- R 4 is hydrogen or C ⁇ -3alkyl; with the proviso that if R 1 is hydrogen or halo, R 3 is phenyl, phenyl-(C ⁇ -6alkyl)-, C3-scycloalkyl, C ⁇ -scycloalkenyl, or naphthyl.
- a particularly preferred compound of formula (XII) is [N-(2- methoxybenzyl)acetylamino]-3-(lH-indol-3-yl)-2-[N-(2-(4-piperidin-l- yl)piperidin-l-yl)acetylamino] propane; or a pharmaceutically acceptable salt thereof.
- a and X are independently selected from the group consisting of H, OH, halogen, NH 2 , SH, phenyl, C1-C30 alkyl, C3-C30 cycloalkyl, C1-C30 substituted alkyl, C3-C30 substituted cycloalkyl, C1-C10 alkyl or C3-C10 cycloalkyl mono- or di- substituted NH 2 , C1-C10 alkoxy, C1-C10 alkyl or
- the alkyl groups can be straight or branched.
- the C1-C30 substituted alkyl and C3-C30 substituted cycloalkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH 2 , Ci-Cio alkyl or C3-C10 cycloalkyl mono- or di- substituted NH 2 , OH, SH, and C1-C10 alkoxy.
- A can include X and X can include A such that the two moieties can form part of the same cyclic structure.
- Preferred compounds of formula (XIII) are those in which A is selected from the group consisting of H, OH, and halogen, X is selected from the group consisting of C1-C30 alkyl, C3-C30 cycloalkyl, C1-C 30 substituted alkyl, C3-C30 substituted cycloalkyl, halogen, C1-C10 alkyl or C3-C10 cycloalkyl substituted thio, and phenyl substituted thio.
- Particularly preferred compounds of formula (XIII) are those in which A is selected from the group consisting of H, OH, and Cl, and X is selected from the group consisting of C1-C30 alkyl, C3-C30 cycloalkyl, C1-C30 substituted alkyl, C3-C30 substituted cycloalkyl, Cl, and chlorophenylthio.
- A is OH and X is 4-aminobutyl, i.e. alendronate.
- Non-limiting examples of bisphosphonates useful herein include the following:
- Alendronate also known as alendronate sodium or monosodium trihydrate
- l,l-dichloromethylene-l,l-diphosphonic acid (clodronic acid), and the disodium salt (clodronate, Procter and Gamble), are described in Belgium Patent 672,205 (1966) and J. Org. Chem 32, 4111 (1967), both of which are incorporated by reference herein in their entirety.
- l-hydroxy-3-(l-pyrrolidinyl)-propylidene-l,l-bisphosphonic acid EB-1053
- l-hydroxyethane-l,l-diphosphonic acid (etidronic acid).
- alendronate More preferred is alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- estrogen receptor modulators are known for use in hormone replacement therapy and for their anti-bone resorption benefits.
- Nonlimiting examples of estrogen receptor modulators useful herein include estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.
- Further examples of estrogen receptor modulators include clometherone, delmadinone, droloxifene, idoxifene, nafoxidine, nitromifene, ormeloxifene (centchroman), toremifene, trioxifene, BE-25327, CP-336156 and ([2-(4-hydroxyphenyl)-6-hydroxynaphthalen-l- yl][4-[2-(l-piperidinyl)ethoxy]phenyl]methane, and their pharmaceutically acceptable salts, and mixtures thereof.
- Non-limiting examples of an androgen receptor modulators include danazol, 5a-dihydrotestosterone, testosterone, nandrolane decanoate, methyltestosterone, methanadrostenolone, stanozolol, fluoxymesterone, oxymetholone, oxandrolone, oxymethol, norethandrolone, ethylestranol, 4-androsten-19-al-3, 17-dione, 19-nortestosterone, norethandiOne, norethisterone, dehydroepiandrosterone, epiandrosterone sulfate, androstenedione and androstenediol, testosterone propionate, testosterone cytpionate, and testosterone enanthate.
- a peptide hormone useful herein is calcitonin, w iich is approved for use for treating osteoporosis. Both human and salmon calcitonin are useful herein.
- the preferred compounds of formulae (I), (II) and (III) will have the 2- and 3-substituents on the morphohne ring in the cis arrangement, the preferred stereochemistry being as shown in the following general formula:
- the preferred stereochemistry of the ⁇ -carbon is either (R) when the substituent is an alkyl (e.g. methyl) group or (S) when the substituent is a hydroxyalkyl (e.g. hydiOxymethyl) group.
- the preferred compounds of formula (IV) will have the stereochemistry of the 5- and 6-positions as shown below (5-(R), 6-(S ). Where the optional double bond shown in formula (IV) is absent, the particularly preferred compounds will have the stereochemistry of the 3-position as shown below (3-(i?)):
- suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight- chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
- suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.
- suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
- suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclop r o yl and cyclohexyl. Unless otherwise defined herein, suitable aryl groups include phenyl and naphthyl groups.
- a particular aryl-C, .6 alkyl, e.g. phenyl-Ci-calkyl, group is benzyl.
- suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.
- halogen as used herein includes fluorine, chlorine, bromine and iodine.
- Suitable pharmaceutically acceptable salts of the NK- 1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.
- Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group.
- the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.
- the compounds of use in this invention may have one or more chiral centers and the present compounds may occur as racemates, racemic mixtures and as individual diasteriomers or enantiomers with all such isomeric forms and mixtures thereof being included within the scope of this invention.
- some of the crystaUine forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds of the instant invention may form solvates with water or common organic solvents.
- Nonhmiting examples of salts include those selected from the group consisting alkali metal, alkaline metal, ammonium, and mono-, di, tri-, or tetra-C ⁇ -C3o-alkyl-substituted ammonium.
- Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
- Nonhmiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.
- bisphosphonate and “bisphosphonates”, as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
- the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those or ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, unless indicated otherwise herein.
- the phrase "about 70 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis” means that the amount of the bisphosphonate compound selected is calculated based on 70 mg of alendronic acid.
- the NK-1 receptor antagonist and the bisphosphonate may be formulated in a single pharmaceutical composition or alternatively in individual pharmaceutical compositions for simultaneous, separate or sequential use in accordance with the present invention.
- compositions according to the present invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, by inhalation or insufflation or administration by transdermal patches or by buccal cavity absorption wafers.
- Oral dosage forms are particularly preferred (e.g. tablets, capsules, pills or wafers).
- the principal active ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like; for oral administration in liquid form, e.g., elixirs and syrups, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated.
- Suitable binders can include starch, gelatin, natural sugars such a glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- a particularly preferred tablet formulation for alendronate monosodium trihydrate is that described in U.S. Patent No.
- the compounds used in the present method can also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxylpropyl- methacrylamide, and the like.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- the liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
- Preferred compositions for administration by injection include those comprising a NK- 1 receptor antagonist as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in- water emulsion).
- Suitable surface- active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g.
- compositions with a surface- active agent will conveniently comprise between 0.05 and 5% surface -active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
- Suitable emulsions may be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM and LipiphysanTM.
- the active ingredient may be either dissolved in a pre- mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water.
- an oil e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil
- a phospholipid e.g. egg phospholipids, soybean phospholipids or soybean lecithin
- other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion.
- Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%.
- the fat emulsion will preferably comprise fat droplets between 0.1 and l.O ⁇ m, particularly 0.1 and 0.5 ⁇ m, and have a pH in the range of 5.5 to 8.0.
- Particularly preferred emulsion compositions are those prepared by mixing a NK-1 receptor antagonist selected from the compounds of formulae (I), (ID, (HI), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) and (XII) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
- a NK-1 receptor antagonist selected from the compounds of formulae (I), (ID, (HI), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) and (XII) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine.
- Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- compositions of the present invention may also be presented for administration in the form of trans-dermal patches using conventional technology.
- the compositions may also be administered via the buccal cavity using, for example, absorption wafers.
- the present invention further provides a process for the preparation of a pharmaceutical composition comprising a NK-1 receptor antagonist and a bisphosphonate, which process comprises bringing a NK-1 receptor antagonist and a bisphosphonate, into association with a pharmaceutically acceptable carrier or excipient.
- the NK-1 receptor antagonist and bisphosphonate are presented in a ratio which is consistent with the manifestation of the desired effect.
- the ratio by weight of the NK-1 receptor antagonist and the bisphosphonate will suitably be between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1.
- a suitable dosage level for the NK-1 receptor antagonist about 0.05 to 1500mg per day, preferably about 0.25 to 1500mg per day, and especially about 0.25 to 500mg per day.
- Preferred oral dosages in humans may include lOmg, 30mg, lOOmg and 300mg of the NK- 1 receptor antagonist per dose.
- the compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, especially 1 or 2 times daily.
- a suitable dosage level for the bisphosphonate is between 0.05 mg per kg of body weight per day (mg/kg/day) to about 1.0 mg/kg/day.
- Preferred oral dosages in humans may range from daily total dosages of about 2.5-20 mg/day over the effective treatment period, and a preferred prophylactic amount is 2.5, 5, or 10 mg/day.
- Alendronate may be administered in a single daily dose or in a divided dose. It is desirable for the dosage to be given in the absence of food, preferably from about 30 minutes to 2 hours prior to a meal, such as breakfast, to permit adequate absorption.
- a suitable dosage level for the estrogen or androgen receptor modulator is between about 0.1 and 100 mg/day, and preferably between about 0.1 and 10 mg/day, depending on the potency of the agent.
- the amount of the NK-1 receptor antagonist and (where present) the additional active agent(s) required for use in the treatment or prevention of abnormal bone resorption will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.
- the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) and (XII) may be prepared by the methods described in EP-A-0 577 394 (or WO 95/16679), WO 95/18124, WO 95/23798, WO 97/49710, EP-A-0 436 334, WO 93/21155, EP-A-0 591 040, EP-A-0 532 456, EP-A-0 443 132, WO 92/17449, WO 95/08549 and WO 95/14017, respectively.
- NK-1 receptor antagonists of the formulae (I), (IT), (HI), ⁇ JV), (V), (VI), (VII), (VIII), (IX), (X), (XI) and (XII) for use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (IC ⁇ o) of less than lOOnM.
- NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists with an NK-1 receptor affinity (ICso) of less than lOnM, favourably less than 2nM and preferably less than InM.
- ICso NK-1 receptor affinity
- NK-1 receptor antagonists of use in the present invention are orally active, long acting, NK-1 receptor antagonists, identified using a combination of the following assays:
- ASSAY 1 NK-1 Receptor binding
- NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri et al, J.
- the receptor is expressed at a level of 3xl0 5 receptors per cell.
- Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay.
- 125 I-Tyr 8 -substance P (0. InM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5 ⁇ l dimethylsulphoxide, DMSO) with 5xl0 4 CHO cells.
- Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7.5, containing 5mM MnCls, 150mM NaCl, 0.02% bovine serum albumin (Sigma), 50 ⁇ g/ml chymostatin (Peninsula), O. lnM phenylmethylsulphonyl fluoride, 2 ⁇ g/ml pepstatin, 2 ⁇ g/ml leupeptin and 2.8 ⁇ g/ml furoyl saccharine.
- the incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Non-specific binding is determined using excess substance P (l ⁇ M) and represents ⁇ 10% of total binding.
- NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by central infusion of NK-1 receptor agonists such as GR73632 based on the method of Rupniak & Williams, Eur. J. Pharmacol, 1994, 265, 179.
- Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of approximately 5ml kg i.v.
- test compounds may be administered orally or by subcutaneous or intraperitoneal routes.
- a skin incision is then made in the mi ⁇ hne of the scalp to expose the skull.
- a selective NK-1 receptor agonist e.g. GR73632 (d Ala[L-Pro 9 ,Me-Leu 10 ]-substance P-(7-l l)
- GR73632 d Ala[L-Pro 9 ,Me-Leu 10 ]-substance P-(7-l l)
- a cuffed 27 gauge needle by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma.
- the scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (approximately 25cm x 20cm x 20cm).
- the duration of hind foot tapping is then recorded continuously for approximately 5 minutes. Duration of action may be determined by comparing the effect of the test compound on foot tapping when administered five minutes (i.v.) or 1 hour (p.o.) before NK-1 agonist challenge, against the effect when the test compound is administered 24 hours before the NK-1 agonist challenge.
- ferrets Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately lOOg of tinned cat food. At 60 minutes following oral dosing, cisplatin (lOmg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded by trained observers.
- Long acting NK- 1 receptor antagonists for use in the present invention can be identified by their ability to inhibit abnormal bone resorption induced by ovariectomy in six-month old rats, as described in Wronski et al. Endocrinology 123:681-686 (1988). Since estrogen deficiency is the main risk factor for post-menopausal osteoporosis in people, abnormal bone resorption in the OVX rat model is extremely relevant to the human condition.
- Ovariectomy is completed by dorsal or ventral approach; sham-surgery is completed in age/sex-matched rats. Test compounds are administered orally, subcutaneously, or intraperitoneally to OVX rats beginning the day after surgery. All rats are killed at four weeks post-surgery.
- Bone loss accompanied by accelerated bone resorption and formation in OVX rats is detectable by techniques that are routinely applied in humans. These include measurement of: 1) bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA) in bone regions that contain varying amounts of cortical and trabecular bone (central femur [cortical] and distal femur [trabecular]); 2) urinary deoxypyrichniline crosslinks (uDPD), a biochemical marker of bone turnover; and 3) bone turnover via quantitation of in vivo fluorochrome labelled bone forming surfaces (mineralizing surface; MS/BS) on histologic sections in cancellous bone of the proximal tibia.
- BMD bone mineral density
- DXA dual energy x-ray absorptiometry
- uDPD urinary deoxypyrichniline crosslinks
- MS/BS in vivo fluorochrome labelled bone forming surfaces
- a typical experimental design using the OVX rat assay in an active pre-clinical development program has six groups: a) Sham-operation b) Ovariectomy (OVX) c) OVX+Low Dose NK-1 Antagonist d) OVX+Medium Dose NK- 1 Antagonist e) OVX+High Dose NK- 1 Antagonist f) OVX+.003mpk daily alendronate Alendronate, a known inhibitor of abnormal bone resorption, and a drug already approved for the prevention/treatment of osteoporosis, is used as a positive control.
- a suitable selection cascade for NKi antagonists of use according to the present invention is as follows: (i) Determine affinity for human NKi receptor in radioHgand binding studies (Assay 1); select compounds with IC50 ⁇ lOnM, preferably IC ⁇ o ⁇ 2nM, especially IC50 ⁇ InM.
- step (v) Determine ability of orally- administered compounds to inhibit abnormal bone resorption induced by ovariectomy in adult female rats (Assay 4); select compounds with ID90 (3mg kg p.o., and preferably ID90 (lmg/kg p.o.).
- Particularly preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK- 1 receptor binding criteria of step (i) which, in addition, have ⁇ 5-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.
- HSA human serum albumin
- a NK- 1 receptor antagonist of use in the present invention is the compound 2-(R)-(l-(R)-(3,5-bis(triQuoromethyl)phenyl)- ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo- lH,4H-l,2,4-triazolo)methyl)- morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity:
- a NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(l-(R)-(3,5- bis(trifluoiOmethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl- 1,2,3- triazol-4-yl)methyl-3-(S)-phenylmorpholine, the preparation of which is described in International Patent Specification No. WO 95/18124. In the aforementioned assays, this compound has the following activity:
- IC5o 0.25nM gerbil foot-tapping (5 mins.): i.v. gerbil foot-tapping (24 hrs.): ID50X).17mg/kg i.v.
- formulations may be prepared with separate active ingredients or with a combination of active ingredients in one composition.
- the active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste.
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
- the resulting granulation is then compressed into tablets containing 50mg, lOOmg and 300mg of the NK-1 receptor antagonist per tablet.
- EXAMPLE 2 Bisphosphonate containing tablets are prepared using standard mixing and formation techniques as described in U.S. Patent No. 5,358,941, to Bechard et al., issued October 25, 1994, which is incorporated by reference herein in its entirety.
- Tablets containing about 35 mg of alendronate, on an alendronic acid active basis, are prepared using the following relative weights of ingredients.
- Croscarmellose Sodium, NF 2.0 mg 8.0 g Tablets comprising other relative weights of alendronate, on an alendronic acid active basis may also be prepared: e.g., about 8.75, 17.5, 70, and 140 mg per tablet.
- tablets containing other bisphosphonates at appropriate active levels are similarly prepared: e.g., cimadronate, clodronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, and pharmaceutically acceptable salts thereof.
- tablets containing combinations of bisphosphonates are similarly prepared.
- NK- 1 Receptor Antagonist 50.0 100.0 300.0 Alendronate Monosodium 45.0 45.0 45.0 Trihydrate
- the active ingredients cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste.
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
- the resulting granulation is then compressed into tablets containing 50mg, lOOmg and 300mg of the NK-1 receptor antagonist and 45mg of alendronate monosodium trihydrate per tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99934993A EP1102590A1 (en) | 1998-08-04 | 1999-07-30 | Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
AU50599/99A AU763615B2 (en) | 1998-08-04 | 1999-07-30 | Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption |
JP2000563283A JP2002522389A (en) | 1998-08-04 | 1999-07-30 | Use of an NK-1 receptor antagonist for treating or preventing abnormal bone resorption |
CA002339146A CA2339146A1 (en) | 1998-08-04 | 1999-07-30 | Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9816897.4 | 1998-08-04 | ||
GBGB9816897.4A GB9816897D0 (en) | 1998-08-04 | 1998-08-04 | Therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000007598A1 true WO2000007598A1 (en) | 2000-02-17 |
Family
ID=10836638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/002509 WO2000007598A1 (en) | 1998-08-04 | 1999-07-30 | Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1102590A1 (en) |
JP (1) | JP2002522389A (en) |
AU (1) | AU763615B2 (en) |
CA (1) | CA2339146A1 (en) |
GB (1) | GB9816897D0 (en) |
WO (1) | WO2000007598A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US7030157B2 (en) | 2001-07-31 | 2006-04-18 | Pfizer Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
CN109694390A (en) * | 2017-10-24 | 2019-04-30 | 齐鲁制药有限公司 | A kind of Fosaprepitant nitrogen oxides |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868117B (en) * | 2016-09-28 | 2021-04-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | Stenazole saccharinate and preparation method and application thereof |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0436334A2 (en) * | 1990-01-04 | 1991-07-10 | Pfizer Inc. | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles |
EP0443132A1 (en) * | 1989-12-22 | 1991-08-28 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same |
WO1992017449A1 (en) * | 1991-03-26 | 1992-10-15 | Pfizer Inc. | Stereoselective preparation of substituted piperidines |
EP0532456A1 (en) * | 1991-08-12 | 1993-03-17 | Ciba-Geigy Ag | 1-Acylpiperidine derivatives and their use as substance P antagonists |
WO1993021155A1 (en) * | 1992-04-10 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Perhydroisoindole derivatives as p substance antagonists |
EP0577394A1 (en) * | 1992-06-29 | 1994-01-05 | Merck & Co. Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
EP0591040A1 (en) * | 1992-09-30 | 1994-04-06 | Sanofi | Quaternary basic amides as tachykinines antagonists |
WO1994016697A1 (en) * | 1993-01-19 | 1994-08-04 | Rhone-Poulenc Rorer S.A. | Synergising association having an antagonist effect on nk1 and nk2 receptors |
WO1994022822A1 (en) * | 1993-04-05 | 1994-10-13 | Rhone-Poulenc Rorer S.A. | Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same |
WO1995008549A1 (en) * | 1993-09-22 | 1995-03-30 | Glaxo Group Limited | 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins |
WO1995014017A1 (en) * | 1993-11-17 | 1995-05-26 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
WO1995023798A1 (en) * | 1994-03-04 | 1995-09-08 | Merck & Co., Inc. | Prodrugs of morpholine tachykinin receptor antagonists |
EP0693489A1 (en) * | 1994-07-12 | 1996-01-24 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
WO1996037207A2 (en) * | 1995-05-25 | 1996-11-28 | Biofrontiers, Inc. | Pharmaceutical compositions containing calcium sulfate |
EP0761219A1 (en) * | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-Acylaminopropanamines as growth hormone secretagogues |
WO1997049710A1 (en) * | 1996-06-21 | 1997-12-31 | Merck Sharp & Dohme Limited | Spiro-piperidine derivatives and their use as therapeutic agents |
WO1998043639A1 (en) * | 1997-04-03 | 1998-10-08 | Eli Lilly And Company | Methods of treating bone loss |
-
1998
- 1998-08-04 GB GBGB9816897.4A patent/GB9816897D0/en not_active Ceased
-
1999
- 1999-07-30 WO PCT/GB1999/002509 patent/WO2000007598A1/en not_active Application Discontinuation
- 1999-07-30 JP JP2000563283A patent/JP2002522389A/en not_active Withdrawn
- 1999-07-30 CA CA002339146A patent/CA2339146A1/en not_active Abandoned
- 1999-07-30 AU AU50599/99A patent/AU763615B2/en not_active Ceased
- 1999-07-30 EP EP99934993A patent/EP1102590A1/en not_active Withdrawn
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0443132A1 (en) * | 1989-12-22 | 1991-08-28 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same |
EP0436334A2 (en) * | 1990-01-04 | 1991-07-10 | Pfizer Inc. | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles |
WO1992017449A1 (en) * | 1991-03-26 | 1992-10-15 | Pfizer Inc. | Stereoselective preparation of substituted piperidines |
EP0532456A1 (en) * | 1991-08-12 | 1993-03-17 | Ciba-Geigy Ag | 1-Acylpiperidine derivatives and their use as substance P antagonists |
WO1993021155A1 (en) * | 1992-04-10 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Perhydroisoindole derivatives as p substance antagonists |
EP0577394A1 (en) * | 1992-06-29 | 1994-01-05 | Merck & Co. Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
EP0591040A1 (en) * | 1992-09-30 | 1994-04-06 | Sanofi | Quaternary basic amides as tachykinines antagonists |
WO1994016697A1 (en) * | 1993-01-19 | 1994-08-04 | Rhone-Poulenc Rorer S.A. | Synergising association having an antagonist effect on nk1 and nk2 receptors |
WO1994022822A1 (en) * | 1993-04-05 | 1994-10-13 | Rhone-Poulenc Rorer S.A. | Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same |
WO1995008549A1 (en) * | 1993-09-22 | 1995-03-30 | Glaxo Group Limited | 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins |
WO1995014017A1 (en) * | 1993-11-17 | 1995-05-26 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
WO1995023798A1 (en) * | 1994-03-04 | 1995-09-08 | Merck & Co., Inc. | Prodrugs of morpholine tachykinin receptor antagonists |
EP0693489A1 (en) * | 1994-07-12 | 1996-01-24 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
WO1996037207A2 (en) * | 1995-05-25 | 1996-11-28 | Biofrontiers, Inc. | Pharmaceutical compositions containing calcium sulfate |
EP0761219A1 (en) * | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-Acylaminopropanamines as growth hormone secretagogues |
WO1997049710A1 (en) * | 1996-06-21 | 1997-12-31 | Merck Sharp & Dohme Limited | Spiro-piperidine derivatives and their use as therapeutic agents |
WO1998043639A1 (en) * | 1997-04-03 | 1998-10-08 | Eli Lilly And Company | Methods of treating bone loss |
Non-Patent Citations (2)
Title |
---|
R.A. CHOLE ET AL.: "Adaptive Bone Modeling in the Middle Ear is Substance-P Dependent", AMERICAN JOURNAL OF OTOLOGY, vol. 19, no. 4, July 1998 (1998-07-01), pages 521 - 524, XP000866513 * |
T. GOTO ET AL.: "Light and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone", CELL AND TISSUE RESEARCH, vol. 293, no. 1, July 1998 (1998-07-01), pages 87 - 93, XP000866542 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030157B2 (en) | 2001-07-31 | 2006-04-18 | Pfizer Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
CN109694390A (en) * | 2017-10-24 | 2019-04-30 | 齐鲁制药有限公司 | A kind of Fosaprepitant nitrogen oxides |
Also Published As
Publication number | Publication date |
---|---|
GB9816897D0 (en) | 1998-09-30 |
AU5059999A (en) | 2000-02-28 |
JP2002522389A (en) | 2002-07-23 |
AU763615B2 (en) | 2003-07-31 |
EP1102590A1 (en) | 2001-05-30 |
CA2339146A1 (en) | 2000-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6162805A (en) | Use of an NK-1 receptor antagonist and an SSRI for treating obesity | |
US6232311B1 (en) | Method for treating or preventing psychosomatic and psychoimmunologic disorders | |
US6242446B1 (en) | Method for treating attention deficit disorder | |
AU693235B2 (en) | Combination treatment for inhibiting bone loss | |
AU677700B2 (en) | Methods for inhibiting endometriosis | |
WO2002003976A2 (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens | |
CZ20022401A3 (en) | Pharmaceutical preparation and a kit for reducing or elimination of menopause symptoms | |
WO2002003992A2 (en) | Use of substituted indole compounds for treating prosthesis-related bone degeneration | |
US20020028805A1 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
US20040259850A1 (en) | Method for treating or preventing symptoms of hormonal variation including hot flashes | |
US6054455A (en) | Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia | |
EP1359940A2 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
WO2002003989A2 (en) | Use of substituted indole compounds for treating sphincter incontinence | |
US20020019377A1 (en) | Combination therapy for inhibiting sphincter incontinence | |
AU763615B2 (en) | Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption | |
US6239122B1 (en) | Method of treatment of nausea, vomiting, and other disorders using estrogens | |
AU744261B2 (en) | Use of NK-1 receptor antagonists for treating eating disorders | |
US6090819A (en) | Use of NK-1 receptor antagonists for treating mania | |
AU749976B2 (en) | Method for treating premenstrual or late luteal phase syndrome | |
US20020028792A1 (en) | Combinations of bisphosphonates, estrogens and estrogenic agents | |
US20020142942A1 (en) | Method for treating premenstrual or late luteal phase syndrome | |
US20020025952A1 (en) | Combinations of statins, estrogens and estrogenic agents | |
WO1999025364A1 (en) | Method for treating attention deficit disorder | |
WO1999027938A1 (en) | Method for treating or preventing psychosomatic and psychoimmunologic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999934993 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 50599/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2339146 Country of ref document: CA Ref country code: CA Ref document number: 2339146 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09762083 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999934993 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 50599/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999934993 Country of ref document: EP |